Targeted Oncology spoke with David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president of the Society for Neuro-Oncology, and lead author on the ReACT trial to better understand the significance of the study results for patients with glioblastoma.
The treatment of patients with ovarian cancer has evolved from an approach focused on chemotherapy and surgery to one involving targeted therapies and monoclonal antibodies.
Updated data from a phase II trial of ibrutinib (Imbruvica) in Waldenström’s Macroglobulinemia (WM) showed a 2-year overall survival (OS) rate of 95% with the BTK inhibitor.
Novel combinations and immunotherapies have significantly expanded treatment options for myeloma. Numerous studies, including the ASPIRE and ELOQUENT-2 trials, have shown positive results for triple drug combinations.
In a wide-ranging interview, Thomas Lynch, MD, provides expert insight across the spectrum of care, from screening to the challenges associated with resistance mutations.
A biomarker panel containing circulating tumor cell (CTC) number and LDH level was shown to be a surrogate for overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Intraperitoneal (IP) chemotherapy offers a median 10-month survival advantage over IV chemotherapy for women with advanced ovarian cancer. Result from a retrospective analysis were recently published in the Journal of Clinical Oncology.
The focus in non-Hodgkin lymphoma (NHL) now needs to shift to predictive biomarkers, according to Randy Gascoyne, MD.
Progression on treatment with ibrutinib in patients with chronic lymphocytic leukemia (CLL) was associated with pretreatment BCL6 abnormalities, acquired mutations in BTK and PLCG2, and complex karyotypes.
An orphan drug designation has been granted to Reolysin (wild-type reovirus) for the treatment of patients with ovarian cancer.
Changing the administration schedule for gemcitabine plus nab-paclitaxel (Abraxane) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer.
A “watch and wait†surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery. This retrospective review of clinical data was presented at the 2015 Gastrointestinal Cancers Symposium.
February 14th 2015
March 23rd 2015
March 27th 2015
April 8th 2015
